Researchers at the Kennedy Institute and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, working with clinicians at NHS Lothian, have found that injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules results in the reduction of the cell characteristics responsible for progression of Dupuytren’s disease.
Based on their laboratory data that tumour necrosis factor (TNF) drives the development of myofibroblasts, the cell type that causes Dupuytren’s disease, the research team explored the effect of an anti-TNF drug injected directly into the Dupuytren’s nodule tissue. The results so far are very promising.
“Our data have shown that a concentrated formulation of adalimumab injected directly into the diseased tissue may be effective in targeting the cells responsible for Dupuytren’s disease,” said Jagdeep Nanchahal, MD, PhD, University of Oxford Professor of Hand, Plastic and Reconstructive Surgery, who led the study.
“This brings new hope to people who suffer from this disabling condition, who currently have to wait for their situation to be deteriorate, watching their hand lose function until it is bad enough for surgery. And then there’s the lengthy recovery ahead, a less than ideal situation to find yourself in.”
This randomised trial (phase 2a) recruited 28 patients with Dupuytren’s disease who were scheduled to have surgery in Edinburgh to remove diseased tissue in their hand. Two weeks prior to surgery they received a single injection of varying doses of the anti-TNF drug, or placebo. The tissue removed during surgery, which is usually discarded, was then analysed in the laboratory. The team found that adalimumab (at a dose of 40mg formulated in 0.4ml) reduces expression of the fibrotic markers, -smooth muscle actin (-SMA) and type I procollagen, at 2 weeks post injection, suggesting this drug could be used to stop the growth of disease causing myofibroblast cells. They also found the drug to be safe and well tolerated.
The findings are published on line in the journal EBioMedicine, published by The Lancet.
Dupuytren’s disease is a common condition of the hand that affects 4% of the UK population and causes the fingers to curl irreversibly into the palm. There is currently no NICE approved treatment for early disease and typically people are told to return to their GP once their fingers become so bent that their hand function is impaired.
The anti-TNF drug adalimumab (Humira) is currently licensed in the EU for the treatment of a number of conditions including rheumatoid arthritis, Crohn’s disease and ulcerative colitis and overall has an excellent safety profile.
“We are delighted to have received further funding from the Wellcome Trust and Department of Health to test whether adalimumab will work for patients with early stage Dupuytren’s disease,” said Professor Sir Marc Feldmann, co-author and former director of the Kennedy Institute. In conjunction with Professor Sir Ravinder Maini, Sir Marc identified TNF as a therapeutic target in patients with rheumatoid arthritis.
“The Kennedy Institute has a long history of successfully translating laboratory findings to the clinic'” said Professor Fiona Powrie, Director of the Institute. “This type of work requires close collaboration between laboratory scientists, clinical trialists and clinician scientists over many years”.
The researchers are continuing to investigate the use of this drug to treat Dupuytren’s disease in a phase 2b trial called the RIDD trial, which is currently running in Oxford and Edinburgh.
The Latest on: Dupuytren’s disease
via Google News
The Latest on: Dupuytren’s disease
- 180 Life Sciences Provides Follow-Up Information on Oxford University and the Company’s Successful Dupuytren’s Phase 2b Clinical Trial Resultson December 6, 2021 at 5:15 am
Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory ...
- 180 Life Sciences Corp. (ATNF) is set for a tempting yields with an average volume of 1.04Mon December 6, 2021 at 5:01 am
Let’s start up with the current stock price of 180 Life Sciences Corp. (ATNF), which is $3.27 to be very precise. The Stock rose vividly during the last session to $3.95 after opening rate of $3.88 ...
- 180 Life Sciences Sees Positive Results From Trial for Dupuytren's Disease Treatmenton December 6, 2021 at 4:42 am
By Chris Wack 180 Life Sciences Corp. said it saw positive results from its Phase 2b clinical trial for Dupuytren's disease. The company said the Phase ...
- 180 Life Sciences: Positive Data From Dupuytren’s Disease Study Could Be a Big Catalyst, Says Analyston December 1, 2021 at 3:09 pm
Nanchahal’s presentation is called ‘Re-purposing anti-TNF for Dupuytren’s Disease’ and will be given at the 2021 International Dupuytren Symposium which takes place today (Wednesday ...
- First US case of Omicron coronavirus variant reportedon December 1, 2021 at 11:51 am
The Centers for Disease Control and Prevention said on Wednesday the infected individual had recently returned from South Africa. The traveller was fully vaccinated, has displayed mild symptoms so far ...
- 180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposiumon November 30, 2021 at 4:00 pm
Professor Nanchahal will present his work on unravelling the molecular mechanisms underlying the pathogenesis of Dupuytren’s disease leading to the identification of anti-tumor ...
- 180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposiumon November 18, 2021 at 5:18 am
Professor Nanchahal will present his work on unravelling the molecular mechanisms underlying the pathogenesis of Dupuytren’s disease leading to the identification of anti-tumor necrosis factor (“TNF”) ...
- 180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposiumon November 18, 2021 at 12:40 am
The MarketWatch News Department was not involved in the creation of this content. PALO ALTO, Calif., Nov 18, 2021 (GLOBE NEWSWIRE via COMTEX) -- PALO ALTO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE ...
- Dupuytren’s disease—etiology and treatmenton November 15, 2021 at 1:58 pm
2. Rombouts JJ, Noel H, Legrain Y, Munting E: Prediction of recurrence in the treatment of Dupuytren’s disease: evaluation of a histologic classification. J Hand Surg Am. 1989; 14: 644–52 ...
via Bing News